- Germany
- /
- Medical Equipment
- /
- XTRA:NN6
NanoRepro First Half 2023 Earnings: €0.21 loss per share (vs €0.016 profit in 1H 2022)
NanoRepro (ETR:NN6) First Half 2023 Results
Key Financial Results
- Revenue: €1.39m (down 95% from 1H 2022).
- Net loss: €2.65m (down from €204.5k profit in 1H 2022).
- €0.21 loss per share (down from €0.016 profit in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NanoRepro shares are up 2.7% from a week ago.
Risk Analysis
You still need to take note of risks, for example - NanoRepro has 3 warning signs we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if NanoRepro might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:NN6
NanoRepro
Develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.
Flawless balance sheet moderate.
Market Insights
Community Narratives

